1,721,111 research outputs found
Update on anticancer drugs
No full textUpdate on anticancer drugs. A thorough review of the clinical trials published over the last two years in major medical and oncological journals on a comprehensive spectrum of oncological conditions aims to provide at the same time (as the authors are well known representatives of the critical and complementary competences of clinical care and research methodology) an interesting double opportunity of update on: a) what is truly (i.e.documented and reliable) innovative and deserves adoption in daily care,vs what is either purely suggestive or clearly misleading; b) what are the methological, concrete, simple rules to observe in a field which is certainly moving fast, but at the same time generates highly controversial behaviors in research as well as in daily practices. The accompanying editorial (pag 60-63) further illustrates the way and the yield of using this material and approach both in the areas of nursing sciences and practice
Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis.
No full textState of the art of antiemetic therapy
No full textDespite relevant progress achieved in the last 30 years for the prevention of chemotherapy-induced emesis, nausea and vomiting continue to be among the most distressing adverse events induced by chemotherapy. Emesis is a complex phenomenon, and the precise mechanism by which chemotherapy induces nausea and vomiting is not well known. Many neurotransmitters are involved, and several antiemetic drugs are available. Complete control of vomiting could be achieved in about 70-90% of patients with a better combination of antiemetic drugs. Recently, international guidelines to prevent chemotherapy-induced nausea and vomiting have been updated, and it is very important to know these recommendations and to use them correctly in our clinical practice. However, several aspects of antiemetic therapy will be clarified in the coming years: the improvement of nausea control, the prophylaxis of emesis induced by oral therapies, and the prevention of emesis induced by chemoradiation therapy
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines
No full textPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
No full textBackground: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations
- …
